Hypertensive emergencies occur when high blood pressure is associated with the presence of acute endorgan damage, such as hypertensive encephalopathy. There is controversy as to when and which antihypertensive drugs to use in these situations. Using a comprehensive search strategy in electronic sources, MEDLINE, EMBASE and Cochrane clinical trial register, we conducted a systematic review to look all randomized control trials (RCTs) that compare an antihypertensive drug versus placebo, no treatment or another antihypertensive drug. Fifteen RCTs (representing 869 patients) met the inclusion criteria. Two trials included a placebo arm. All studies (except one) were open-label trials. Seven drug classes were evaluated in those trials: nitrates (nine trials), angiotensin-converting enzyme inhibitors (seven), diuretics (three), calcium channel blockers (six), a-1 adrenergic antagonists (four), direct vasodilators (two) and dopamine agonists (one). Mortality event data were reported in seven trials. Due to insufficient data, no meta-analysis was performed for clinical outcomes. Differences in blood pressure changes between antihypertensives were minor. There is no RCT evidence demonstrating that antihypertensive drugs reduce mortality or morbidity in patients with hypertensive emergencies. Furthermore, there is insufficient RCT evidence to determine which drug or drug class is most effective in reducing mortality and morbidity. There were some minor differences in the degree of blood pressure lowering when one class of antihypertensive drug is compared to another. However, the clinical significance is unknown. RCTs are needed to assess different drug classes to determine initial and longer-term mortality and morbidity outcomes.
Introduction
A hypertensive emergency is the clinical setting where a marked elevation of blood pressure is associated with acute end-organ damage, for example, hypertensive encephalopathy or aortic dissection. As such it is a life-threatening condition. The goal of treatment is to reverse the end-organ damage, prevent adverse outcomes and prolong life. This review focuses on blood pressure lowering drugs that are used in this emergency setting.
The management of hypertension in these emergency situations represents a significant therapeutic challenge. Many antihypertensive drug classes have been used with the objective of rapidly reducing blood pressure, and the expectation of reducing adverse clinical outcomes. This approach was first recommended by Gifford 1 based on a series of eight cases with hypertensive encephalopathy that were treated with sodium nitroprusside. On the basis of this case series evidence this approach has become and remained the standard of care and is currently recommended by most if not all guideline committees (such as JNC-7
2 ). At issue in this review is whether randomized control trial (RCT) evidence supports this approach and which drug classes are the most effective.
Two published systematic reviews have addressed these issues. One compares different antihypertensive drugs, but it pools hypertensive emergency and urgency trials. 3 Urgencies are defined as marked elevated blood pressure in an otherwise stable patient (that is, without acute end-organ damage). In our opinion the urgency setting is very different from that of emergencies and needs to be reviewed separately.
The second systematic review, a Cochrane review of interventions that alter blood pressure after acute stroke is not limited to RCTs studying drugs to reduce blood pressure and includes RCTs whether or not the patients had elevated blood pressure. 4 Therefore, it also does not answer the question raised here.
Objectives
General. The general objective is to find and quantify the RCT evidence for antihypertensive drug treatment of patients with a hypertensive emergency, defined as marked hypertension associated with acute end-organ damage.
Specific. The specific objective is to answer the following two questions:
Does antihypertensive drug therapy as compared to placebo or no treatment affect mortality and morbidity in patients with a hypertensive emergency?
Does one first-line antihypertensive drug class offer a therapeutic advantage, in terms of mortality and morbidity, over another in patients with a hypertensive emergency?
Criteria for considering studies for this review Types of studies. All unconfounded, truly RCTs that compare a first-line antihypertensive drug class versus placebo, no treatment or another first-line antihypertensive drug class. Crossover trials were excluded. There was no language restriction.
Types of participants. Participants must meet the following hypertensive emergency definition: any clinical setting where patients present with marked elevation of blood pressure in the presence of acute end-organ damage. Examples of acute end-organ damage are the following: myocardial infarction, unstable angina, acute left ventricular failure with pulmonary oedema, acute aortic dissection, encephalopathy, stroke and life-threatening bleeding (intracerebral haemorrhage and subarachnoid haemorrhage).
Thus, patients with marked elevation of blood pressure but without acute end-organ damage (defined as urgencies) were not included.
There is no evidence as to what constitutes 'marked blood pressure elevation'. Therefore, we have chosen blood pressure level(s) commonly used in clinical practice to mandate the use of antihypertensive drugs (along with other acute therapy such as pain management) in relevant clinical settings. For example, for patients with acute myocardial infarction a systolic blood pressure (SBP) greater or equal to 180 and or diastolic blood pressure (DBP)X110 mm Hg is the threshold above which thrombolysis is contraindicated (ACC/ AHA-5 ). For patients with acute aortic dissection or with left ventricular failure and pulmonary oedema an SBP greater or equal to 120 mm Hg and or DBPX70 mm Hg is the threshold for therapy. 6, 7 For patients with intracranial haemorrhage or subarachnoid haemorrhage an SBPX160 mm Hg is the threshold because of a higher incidence of rebleeding above this level. 8 For patients with any other acute end-organ damage setting an SBPX180 and or DBPX110 mm Hg is the defined threshold.
We included all RCTs that included patients with these minimum or higher thresholds. In the case that an RCT does not define blood pressure inclusion criteria but had included only one category of patients (patients with pulmonary oedema, for example), then the mean baseline blood pressure had to be equal to or greater than these defined thresholds. In the event that an RCT had included patients with different end-organ damage clinical settings, a mean baseline blood pressure of SBPX180 and or DBPX110 mm Hg is acceptable for inclusion.
Note that pregnancy-related hypertensive emergencies are excluded from this review.
Types of interventions
Intervention: A first-line antihypertensive drug class (first-line antihypertensive drug classes include: nitrates, b-blockers, angiotensin-converting enzyme (ACE) inhibitors, diuretics, calcium channel blockers (CCBs), dopamine agonists, a-adrenergic antagonists and direct vasodilators (diazoxide and hydralazine).
Control: placebo, no treatment or a different firstline antihypertensive drug class.
Types of outcome measures
Primary outcome measures include: total serious adverse events, all-cause mortality and composite of non-fatal cardiovascular events, including myocardial infarction, unstable angina, dissection of aortic aneurysm, acute renal failure, stroke and respiratory failure (necessitating mechanical ventilation).
Secondary outcome measures include:
weighted mean change in SBP, DBP and in heart rate (HR), during the treatment period and withdrawals due to adverse effects.
Methods of the review

Data abstraction
The search strategy for identification of studies is summarized in Table 1 . Two reviewers (MIP and MVM) independently decided whether a trial was included. They also independently extracted and entered the data from the included studies. Discrepancies were resolved by discussion. Absence of consensus was resolved by a third reviewer (JMW).
A modified Cochrane quality scoring system was used for concealment of allocation and blinding: A 
Analyses
For the synthesis and analysis of the data Cochrane review manager software Revman 4.2.9 was used.
Relative and absolute risk differences (with 95% confidence interval (CI)) were calculated for dichotomous outcomes for each trial on an intention to treat basis. Heterogeneity between trial results was tested using w 2 -test, where po0.05 was taken to indicate significant heterogeneity. The fixed effect model was used when there was homogeneity and the random effect model was used to test for statistical significance where there was heterogeneity.
Trials were not subclassified according to dose or dosing regimen. Data for blood pressure was combined using a weighted mean difference (WMD) method, whereby the trials are weighted according to the number of subjects in the trial and the within-study variance. Some of the trials did not report a within-study variance for blood pressure reduction. In these studies standard deviation (s.d.) was imputed using the following hierarchy:
(1) Pooled s.d. calculated either from the t-statistic corresponding to an exact p-value reported or from the 95% CI of the mean difference between treatment group and comparative group. Several sensitivity analyses were pre-planned to test robustness, including the use of both fixed and random effects models, 95 and 99% CIs, and quality of trials. Also sensitivity analyses were pre-planned according to the clinical setting and to the class of drug.
Results
Description of studies Our search strategy yielded 86% of irrelevant studies in the first screening stage by reading titles and abstracts ( Figure 1 ). Fifteen RCTs (869 patients) were found that satisfied the inclusion criteria [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] ( Table 2) . Two trials were placebo controlled. 12, 18 Only one trial 12 was confirmed to be double blind, whereas the rest were open label. No trial was designed for or had the power to detect differences in clinical outcomes .The largest trial consisted of 133 patients. 20 The longest trial 11 lasted 10 days. Most of the trials reported data for only 2-6 h. Seven drug classes were evaluated: nitrates (9 trials), ACE inhibitors (7), CCBs (6), peripheral a-1 blockers (4), diuretics (3), direct vasodilators (2) and dopamine agonists (1).
All included trials had patients with elevated blood pressure in the presence of acute end-organ damage. Blood pressure entry criteria differed among trials. Four trials were included on the basis of their mean blood pressure values at baseline. 10, 12, 17, 18 Seven trials included exclusively patients with acute pulmonary oedema. 10, 12, 14, 17, 20, 21, 23 One trial included exclusively patients with hypertensive encephalopathy. 16 There was no trial that included exclusively patients with acute aortic dissection or acute myocardial infarction. Thus, the rest of seven trials included a diverse population with different acute end-organ damage. Only two trials 9,15 reported the s.d. of the change of blood pressure. In the rest of the trials this measure of variability was imputed from the s.d. at end point.
Additional information was required and requested from all included trials. One trialist 9 provided missing information in the original publication. The rest of the trialists did not reply to our request.
We excluded 27 clinical trials for several reasons:
Several trials mixed patients with and without acute end-organ damage in the same RCT (12 trials). [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Other trials included patients without explicitly stating whether patients had acute end-organ damage or not (7 trials). [36] [37] [38] [39] [40] [41] [42] Some trials included non-randomized participants in the trial's results (1 trial). 43 One trial did not report any of the outcomes of interest (1 trial). 44 Two trials did not fulfil blood pressure threshold criteria. 45, 46 One was a cross-over trial. 47 Two trials had wrong comparators (1 compared different doses of the same combination therapy; 48 1 compared two drugs of the same class. 49 One RCT only included responders to a previously given antihypertensive therapy. 50 Two out of 27 excluded trials involved a b-blocker arm and 18/27 excluded trials involved a calcium channel blocker arm. One excluded trial studied exclusively patients with acute aortic dissection. 49 Methodological quality of included studies All studies, except one, 12 were open-label trials. The method of randomization was not reported in eight trials. The method to achieve concealment of allocation was reported in only two trials. 12, 16 Comparisons according to outcomes Total serious adverse events. No trial reported total serious adverse events.
All-cause mortality. Mortality was reported in seven trials 9, 10, 14, 16, 17, 20, 21 and totalled six deaths in three RCTs. The group to which the dead patients were originally allocated was not reported for five of the Figure 1 Quorum flowchart of studies. deaths. In one RCT, a patient treated with hydralazine died of a rupture of the inter-ventricular septum. 21 In four trials mortality was reported as nil. In eight trials there was no mention of mortality. It is possible that there were no deaths during the short range of followup (6-24 h), but it is impossible to be certain.
Different interventions for hypertensive emergencies
Non-fatal cardiovascular events
Composite. Cardiovascular events were reported in five trials. 10, 12, 14, 16, 20 No trial reported cardiovascular events as a composite. It was not possible to extract events from the original trials and analyse them as a composite due to a risk of double-counting the events.
Myocardial infarction. One placebo-controlled trial 12 reported this outcome. There was no statistically significant difference between ACEi and placebo (RR 0.72, 95% CI 0.31-1.72).
Three head-to-head trials reported this outcome. 10, 16, 20 There was no statistical difference in myocardial infarction between nitrates (2.7%) and aadrenergic antagonist (5%) (RR 0.55, 95% CI 0.09-3.17); or nitrates (16%) vs diuretics (12.5%) (RR 1.30,95% CI 0. 40-4.19) ; or between diazoxide (3.5%) vs dihydralazine (4%), (RR 0.86, 95% CI 0.06-12.98).
Pulmonary oedema requiring mechanical ventilation. Three trials reported this outcome. 12, 14, 20 There was no meta-analysis performed since there was only one trial for each comparison. There was no statistically significant difference between captopril and placebo (RR 0.40, 95% CI 0.09-1.86), nitrates and a-adrenergic antagonist (RR 4.12, 95% CI 0.20-84.24 or between nitrates and ACE Inhibitor (RR 0.33, 95% CI 0.01-7.78).
Other than the above, the trials did not report any of our list of cardiovascular events (unstable angina, dissection of aortic aneurysm, acute renal failure or stroke). An additional cardiovascular event was reported that was not on our list: asystole, which happened in one patient randomized to an ACE inhibitor.
14 Withdrawals due to adverse events. Only one trial comparing an a-blocker with nitroglycerine reported withdrawal due to adverse events. 20 There were no significant differences between these two drugs classes (5 vs 2.7%; RR 3.38, 95% CI 0.17-68.84).
Weighted mean change in blood pressure and HR during treatment. For this secondary outcome all trials provided some data and we were able to pool this data.
Drug vs placebo or no treatment. Although we included two placebo-controlled trials, only one provided SBP or DBP data 18 and this was limited to 1 h of follow-up. In this trial, three classes of antihypertensives were included: calcium channel blocker, ACE inhibitors and a-1 adrenergic antagonists (A1A). The pooled effect showed a statistically significant greater reduction in both, SBP (WMD À13.14, 95% CI, À19.48,À6.80) and DBP (WMD À8.03, 95% CI, À12.61,À3.45) with antihypertensive therapy. There were no data on HR.
It was not possible to extract blood pressure data from the other placebo-controlled trial. 12 ] In addition to not reporting any measurement of variability, this trial reported blood pressure data as change in mean arterial pressure (MAP).
Nitrates vs diuretics. Three trials compared nitrates to diuretics (Beltrame, Nelson and Verma) 10, 17, 21 . Furosemide was the common diuretic used in all of them with two nitrates, nitroglycerine and isosorbide as comparators. Neither SBP-nor DBP lowering effect was statistically different between the two classes of drugs. However, in Beltrame, 10 the SBP lowering effect of both drugs was greater (À21 mm Hg for furosemide; À23.75 mm Hg for nitroglycerin) than that reported in the other two trials ( þ 1.0, þ 1.6 mm Hg for furosemide groups and À6, À8 mm Hg for isosorbide groups, respectively). The reasons for that difference across trials are not clear. Despite these differences, heterogeneity was not present when pooling all these three trials. HR change was also not significantly different for both classes of drugs.
Nitrates vs a-1 antagonist. Two trials compared the A1A, urapidil, with nitrates. 13, 20 The first trial used nitroprusside and the second used nitroglycerine as comparator. The SBP lowering effect of the two nitrates was similar (À58.4 mm Hg for nitroprusside and À59.5 mm Hg for nitroglycerine). However, the effect of urapidil (administrated at the same dose in both trials) was very different (À37.6 and À73.5 mm Hg). A similar discrepancy was seen for DBP. This heterogeneity precluded the pooling of these trials in a meta-analysis for these outcomes.
Nitrates vs dopamine agonist. For this comparison one trial was included.
11 During 4 h of treatment, nitrates were associated with a statistically significant greater reduction in SBP as compared with a dopamine agonist (WMD À14.00, 95% CI (À27.72, À0.28). There were no differences between these classes in DBP or HR.
Nitrates vs ACE inhibitors. One trial compared a nitrate with an ACE inhibitor.
14 No statistically significant difference was found between the two groups in SBP or DBP or HR.
Nitrates vs calcium channel blockers. By pooling two trials 19, 23 CCBs were not associated with statistically significant differences in SBP or DBP as compared to nitrates. Using the fixed effect model, CCBs were associated with statistically significant increase in HR as compared to the nitrates (WMD 11.76 95% CI (4.45,19.07). However there was significant heterogeneity across trials and this increase was no longer statistically significant when a random effect model was used.
Nitrates vs direct vasodilator. For this comparison one trial was included. 21 There was no statistical difference in SBP or DBP reduction between the two drugs. There was also no significant difference between these classes in HR change.
ACE inhibitors vs calcium channel blockers. Four trials, 9, 15, 18, 22 compared an ACE Inhibitor with a CCB. The pooled data show that CCBs were associated with a significantly greater reduction in DBP as compared with ACE-I (WMD 7.86, 95% CI (4.92, 10.81). No statistically significant difference was found between the two groups in the reduction of SBP. In three trials that reported HR changes, 9, 15, 22 CCBs were associated with a significant increase in HR as compared with ACE inhibitors (WMD 22.91, 95% CI (19.8, 26 .01). However there was significant heterogeneity across trials and this increase was no longer significant when a random effect model was used.
ACE inhibitors vs a-1 adrenergic antagonist. Two trials 18, 22 compared an ACE Inhibitor with an A1A. Both trials used captopril as comparator but one trial used prazosin and the other used ketanserin. The pooled data show that ACE-I were associated with a significantly greater reduction in both SBP and DBP as compared with A1A (SBP WMD À20, 95% CI (À22.85,À17.39); DBP WMD À3.70, 95% CI (À7.08,À0.31). For SBP outcome there was statistically significant heterogeneity across trials. However the difference was still significant when the random effects model was used. No statistically significant difference was found between the two groups in the HR change in the only trial reporting that outcome. 22 Diazoxide vs hydralazine. For this comparison one trial, 16 which dealt with exclusively hypertensive encephalopathy patients, was included. During 4 h of treatment, hydralazine was associated with a statistically significant greater reduction in both SBP (WMD 13.56, 95% CI (3.06,24.06)) and DBP (WMD 14.67, 95% CI (8.01,21.33)) as compared to diazoxide (WMD À14.00, 95% CI (À27.72, À0.28). It is important to mention, though, that there was no measure of variability reported in this trial. Therefore, we imputed the s.d. of the change according to our hierarchy from other trials (last option: weighted mean s.d. of change from all trials; any drug any dose). There were no HR data reported.
Discussion
This is the first systematic review investigating mortality and morbidity outcomes for all RCTs of drug treatment for hypertensive emergencies. A systematic review that combined hypertensive emergencies and urgencies 3 did not include 11 trials included in our systematic review. Furthermore, Cherney's review mixed randomized with nonrandomized trials.
The only other relevant systematic review in relation to hypertensive emergencies is that conducted for acute stroke by BASC. 4 We excluded one trial 46 (n ¼ 16 patients) that the BASC 2001 systematic review had included. The reason for excluding it was because the blood pressure criteria in this trial (4170/95 mm Hg) did not meet our blood pressure threshold criteria (SBPX180 and or DBPX 110 mm Hg). This exclusion does not affect our conclusion for clinical outcomes as this trial did not report clinical outcomes. The other BASC 2001 trials were not included because blood pressure at baseline was not elevated. Thus, these clinical trials did not include hypertensive emergency patients, as we have defined it.
One of the limitations in our review is that most of the included trials were small (average 58 patients per trial). Furthermore, with the exception of Hamilton et al.
12 all trials were of poor quality.
Three included trials deserve further discussion. Hamilton et al., 12 the only double-blind trial, includes patients with acute pulmonary oedema and high blood pressure, and it compared captopril vs placebo. It demonstrates that this high-quality and double-blind trial was ethical and feasible. The Danish II 1986 16 trial was the only trial that included patients exclusively with hypertensive encephalopathy. This was a well-organized multicentre trial, conducted in Denmark, comparing diazoxide vs dihydralazine. Due to its study design, the ethical committee accepted that the informed consent could not be obtained from patients as all of them had symptoms of hypertensive encephalopathy. A downside of this study is the fact that the trialists reported their results in duplicate publications that did not cite the other publications (the original publication, Krogsgaard et al., 51 is not cited in the other duplicate publications, 16, 52, 53 In addition, blood pressure values were not the same in the different publications, and none of the publications reported measures of SBP or DBP variability. The largest trial, Schreiber et al., 20 included 133 patients with acute pulmonary oedema plus high blood pressure, in an out-of-hospital setting, who were randomized to receive either nitroglycerin or urapidil. The ethical committee (Vienna, Austria) agreed that no informed consent had to be obtained at the time of inclusion for randomization. However, the pitfall of this trial is that 16% of all randomized patients were excluded from the analyses that potentially biased the results. Consistent with this, there was significant heterogeneity when this trial was combined with another trial studying the same comparison groups.
In 19 of the excluded trials [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] it was not possible to determine how many patients had acute endorgan damage or merely had elevation of blood pressure. We believe that it would be misleading to include these trials in this review as the impact of antihypertensive drugs is potentially different. If individual patient data could be obtained, the patients with acute end-organ damage could be added to our review.
It was perhaps surprising and definitely disappointing that we could find no RCT evidence to answer the first question we have posed: Does antihypertensive therapy as compared to placebo or no treatment change mortality and morbidity in patients with hypertensive emergencies? The one available placebo-controlled trial demonstrated that blood pressure was reduced with drugs as compared to the control treatment, however, it was too small and of too short duration to assess morbidity and mortality. We feel it is important for physicians to know that this is one of the clinical settings where treatment is not supported by RCT evidence.
Despite the lack of evidence it is not hard to accept the necessity of lowering blood pressure in those clinical settings where the excessive increases in blood pressure are the cause of the end-organ damage. However, this is not necessarily the best approach in settings where the excessive elevations of blood pressure are probably caused by end-organ damage such as high blood pressure in the presence of a cerebrovascular accident. The presently accepted approach for the immediate treatment of hypertensive emergencies in clinical practice is primarily based on a series of cases published in 1959. 1 In this study carried out over a period of 18 months the author demonstrated the ability to reduced blood pressure with nitroprusside, within minutes, in eight patients with hypertensive emergencies (mostly patients with hypertensive encephalopathy), whose blood pressures had remained elevated after treatment with reserpine or hydralazine. However, he did not report clinical outcomes so we do not know whether these patients did better as a result of the blood pressure lowering. Gifford recommended prompt blood pressure reduction in clinical settings other than hypertensive encephalopathy such as intracerebral or subarachnoid haemorrhage or acute left ventricular failure. The lack of RCT evidence leaves the distinct possibility that in some clinical settings defined as hypertensive emergencies immediate antihypertensive therapy could be doing more harm than good.
There is a hypertensive emergency not included in the present systematic review, eclampsia. Due to its pathophysiology and the involvement of the infant as well as the mother, we felt this clinical entity must be studied separately from other hypertensive emergencies and include outcomes in the infant as well as the mother. There is a Cochrane systematic review 54 that has studied the drugs for treatment of very high blood pressure during pregnancy. However, Duley's systematic review was not limited to patients with eclampsia and did not separately report outcomes in the eclampsia patients. To the best of our knowledge there is no systematic review dealing exclusively with eclampsia and antihypertensive treatment. Thus, a systematic review in this specific area is currently needed.
The present review also does not provide any mortality and morbidity evidence from RCTs to inform clinicians as to which first-line antihypertensive drug class provides more benefit than harm in hypertensive emergencies. This lack of evidence was due to the fact that the trials were too small, did not follow the patients for a long enough period of time and frequently failed to report all important outcomes. In addition all the RCTs except one were open-label trials and therefore concealment of allocation was not possible in most cases. Although, these shortcomings of the trials would not likely affect mortality and morbidity outcomes, they could bias blood pressure and HR data.
Neither did we find RCTs that compared different strategies to reduce blood pressure. Thus, how fast or how much blood pressure should be lowered in hypertensive emergencies remains unknown.
Although it is unproven, it is highly likely that antihypertensive therapy is an overall benefit in a hypertensive emergency and therefore a placebocontrolled trial to prove this would be unethical. What is clear is that this is a clinical area where properly conducted randomized trials are badly needed. At the present time RCTs could be conducted to compare different drug classes and treatment strategies, for example, aggressive rapid lowering of blood pressure to a target versus lowering the blood pressure slowly at a defined rate such as 5-10% every 2 h. What is also clear from this review is that any trial must follow patients long term and document mortality and morbidity. One of the best examples of an adequate RCT in an emergency setting is the corticosteroid randomization after significant head injury (CRASH) trial, 55 where 10 000 patients with acute head injury were randomized to intravenous steroids or placebo. Its approach to handle ethical issues could serve as model when conducting a trial with hypertensive emergency patients.
Conclusions
Implications for practice There is no evidence from RCTs that antihypertensive drugs reduce mortality or morbidity in patients with hypertensive emergencies, defined as marked hypertension associated with acute end-organ damage. Furthermore, there is insufficient RCT evidence to determine which drug or drug class is most effective in reducing mortality and morbidity. There were some minor differences in degree of blood pressure lowering between drug classes. However, the clinical significance is unknown.
This review demonstrates a blood pressure lowering efficacy for nitrates, ACE inhibitors, diuretics, a-adrenergic antagonist, CCBs and dopamine agonists. Nitrates (including nitroprusside) have been studied in most. Therefore, if a hypertensive emergency patient cannot be treated as part of an RCT and a nitrate is available, it is a reasonable choice of therapy.
Implications for research
RCTs are needed to assess different blood pressure lowering strategies and different first-line drug classes in patients with hypertensive emergencies. Outcomes in such trials must be mortality and total serious adverse events at different times of followup such as 7 days, 1 month and including at least 6 months of follow-up of all patients.
